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INTRODUCTION
Bacterial translocation (BT) is defined as the passage of viable
indigenous bacteria from the gastrointestinal tract to normal-
ly sterile extraintestinal sites, such as the mesenteric lymph
nodes, spleen, liver, peritoneal cavity and bloodstream (1). It
is known that BT from the gut mucosa in patients with sep-
sis, burn, or trauma causes the systemic sepsis, ultimately lead-
ing to multiple organ failure (2, 3). 
Glutamine (GLN), the most abundant free amino acid in
the circulation, is the primary fuel for cell division and prolif-
eration of the intestine and plays a key role in the transport of
nitrogen between organs (4, 5). Recent studies indicated that
enteral or parenteral GLN reduces BT, and maintains the gut
mucosal integrity (6-8), though there have been some con-
troversies about the effect of GLN on BT (9, 10). Growth
hormone (GH), a strong anabolic hormone, has been reported
to show the prevention of nitrogen loss and the protein spar-
ing effect when it was administered to the patients with
trauma, injury, burn or the patients after operation (11, 12).
There are also controversies concerning the effect of GH on
BT. While some studies reported that the administration of
GH promoted an earlier growth of the intestinal villi and
decreased the BT in animal studies (13, 14), other study did
not show that GH reduced BT (15). Until now, several stud-
ies showed that the combination of both GLN and GH treat-
ment improved the intestinal absorption in short bowel syn-
drome (16), and increased the intestinal GLN uptake in sepsis
or trauma (17). To our knowledge, however, the combined
effect of GLN and GH on BT in sepsis has remained unknown.
In this study, we investigated the combined effect of GLN
and GH on BT. For this purpose, portal blood culture, bacteri-
al colony counts obtained from mesenteric lymph node culture,
gut mucosal thickness, malondialdehyde (MDA), and gluta-
thione (GSH) content were measured in septic rat induced
by endotoxin.
MATERIALS AND METHODS
Experimental preparation
This study was approved by the Clinical Research Institute
and Laboratory for Experimental Animal Research. Forty eight
specific pathogen free male Sprague-Dawley rats weighing
280-310 g were kept with a 12 hr light-dark cycle and allowed
ad lib access to chow and water. Animals were fasted 8 hr before
the experiment, and anesthetized with an intramuscular injec-
tion of 5 mg of ketamine hydrochloride/100 mg of body we-
ight. To make a sepsis model, each rat was given a single in-
traperitoneal injection of 10 mg/kg of lipopolysaccharide (LPS,
Sigma). After LPS treatment, all rats were administered with
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Combined Administration of Glutamine and Growth Hormone
Synergistically Reduces Bacterial Translocation in Sepsis
We investigated the combined effect of glutamine (GLN) and growth hormone (GH)
on bacterial translocation (BT) in sepsis. After single intraperitoneal injection of lipo-
polysaccharide (10 mg/kg), 48 rats were divided randomly into four groups of 12 ani-
mals each: the control group received chow orally; the GLN group received chow
plus 10% GLN; GH group received chow plus GH; and the GLN/GH group received
chow, 10% GLN, and GH. Twenty-four and 96 hr later, rats were sacrificed. Portal
blood culture, bacterial colony counts of cultured mesenteric lymph nodes, mucos-
al thickness, malondialdehyde (MDA), and glutathione (GSH) levels in the gut mucosa
were measured. There was no significant change of the rate of portal blood culture
between all treatment groups at 24 and 96 hr. At 24 hr, the rats receiving combined
treatment of GLN and GH showed lower bacterial colony counts and mucosal MDA
levels than the control rats, and higher mucosal GSH levels than the control and GLN-
treated rats. At 96 hr, rats treated with both GLN and GH exhibited lower bacterial
colony counts and mucosal MDA levels, and higher mucosal thickness and GSH
levels than control, GLN, or GH-treated rats. This study suggests that the combina-
tion of GLN and GH may synergistically reduce BT over time in sepsis. 
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50 mL/kg of 0.9% saline subcutaneously for resuscitation.
Study design
The rats were assigned to one of the four groups (n=12 in
each group) after LPS treatment: the control group received
chow and water; the GLN group received chow and water and
additionally was given 2 mL of 10% GLN via a metal gavage
into the stomach every 8 hr; the GH group received chow
and water and intramuscular injection of 2.0 I.U./kg/day of GH
(recombinant human GH, LG chemistry, Korea); and the GLN/
GH group received chow and water, 2 mL of 10% GLN every
8 hr, and 2.0 I.U./kg/day of GH. Six animals in each group were
anesthetized with ketamine hydrochloride (7.5 mg/100 mg
intramuscularly) at 24 and 96 hr following LPS treatment,
respectively. After the abdominal cavity was opened, the
mesenteric lymph nodes were removed aseptically and placed
in the ice box. The distal 30 cm of the terminal ileum proxi-
mal to the ileocecal valve was rapidly removed, and the distal
2 cm of the termial ileum was put into 4% paraformalde-
hyde solution for the measurement of the mucosal thickness.
The remaining ileum was longitudinally opened, and thor-
oughly washed with cold 0.9% saline. To separate the mucosa
from the muscle and serosa of the intestine, the removed ter-
minal ileum was scraped on cold slide glass using another
slide glass. Separated mucosa tissues were rapidly frozen
between two blocks of dry ice and stored at -70℃ for sub-
sequent biochemical assays.
Mesenteric lymph node and portal blood cultures
To determine bacterial colony counts, the mesenteric lymph
nodes were aseptically and carefully obtained. The fresh mesen-
teric lymph nodes were weighed and homogenized aseptically
after 0.5 mL of 0.9% saline was added. Aliquots (0.2 mL) of
each of the homogenized lymph nodes solution were plated on
blood and McConkey agar culture plates. All culture plates were
aseptically incubated at 37℃ in the clean bench and exam-
ined for growth at 24 and 48 hr. The values of mean colony
counts obtained from the agar plates were expressed as the co-
lony-forming unit per gram of the mesenteric lymph nodes
(CFU/g of mesenteric lymph nodes). When the abdominal
cavity was opened, portal blood (0.2 mL) was collected under
the microscope, and cultured aerobically and anaerobically
using BAC-TEC broth and Thioglycollate broth, respective-
ly. Blood cultures were continuously monitored for 7 days.
When the culture broth looked turbid, organisms in the cul-
ture broths were identified by standard bacteriological tech-
niques using blood and chocolate agar plates. 
Measurement of mucosal thickness
Samples of the intestinal tissues were fixed in 4% paraform-
aldehyde and dehydrated with alcohol and then paraffin-embe-
dded. The formatted specimens were cut by sliding microtome
and stained with hematoxylin and eosin. Five slide samples
were made in each intestinal sample and the mucosal point
with the longest villi in each slide was measured. Morphome-
tric measurements were performed using an image analyzer
(Image-Pro Plus). Slide samples were randomly chosen for
each animal and examined under oil using an Olympus BH2
microscope. For each animal, 20 randomly chosen mucosal
regions were traced. The thickness of the gut mucoa was ex-
pressed as the mean of these measurement values ( m).
Biochemical assays
To assess the mucosal integrity indirectly, gut lipid peroxida-
tion and antioxidant defenses were measured. Malondialdehyde
(MDA), a byproduct of lipid peroxidation, was measured by
the method of Ohkawa et al. using the thiobarbituric acid (18).
The level of MDA was presented as nmol/g of tissue. Gut
GSH content, antioxidant defenses, was measured according
to the DTNB-GSSG Reductase Recycling Assay of Griffith
(19), which provides a very sensitive assay for total tissue glu-
tathione as described by the following equation.
GSH=total glutathione-0.5×GSSG (oxidized glutathione)
Values were expressed as  mol/g of tissues.
Statistical analysis
SPSS for Windows release 10.0 was used for the statistical
analysis. The statistical significance among the mean values in
the four treatment groups was determined by nonparametric
Kruskal-Wallis test. Mann-Whitney U test was used to com-
pare the mean values in two treatment groups. The values were
expressed as mean±standard deviation. Chi-square test was
also done to compare the portal blood culture rates between
the treatment groups. Nonparametric Spearman’ s correlation
test was used to determine the correlation between the mea-
sured parameters. A pvalue of <0.05 was considered to be sta-
tistically significant.
RESULTS
Portal blood culture and bacterial colony count of mesen-
teric lymph node culture
All organisms in positive portal blood cultures were Esche-
richia coli. There were no significant changes of the positive
culture rates of the portal blood between all treatment groups
at 24 and 96 hr, respectively: control (3/6) vs GLN (2/6) vs
GH (2/6) vs GLN/GH (0/6) at 24 hr (p=0.280) and control
(2/6) vs GLN (0/6) vs GH (0/6) vs GLN/GH (0/6) at 96 hr (p=
0.088), respectively. There was a significant decrease in bac-
terial colony counts in the GLN, GH, and GLN/GH groups
compared with the control group at 24 hr (p=0.026, p=0.004,Glutamine and Growth Hormone and Bacterial Translocation 19
p=0.002, respectively). At 96 hr, both the GLN/GH (p=0.002)
and GH (p=0.009) groups showed a significant decrease in
bacterial colony counts compared with the control group. There
was also a significant decrease in bacterial colony counts at 96
hr in the GLN/GH group compared with the GLN (p=0.041)
and GH (p=0.041) groups (Fig. 1A).
Mucosal thickness
There were no significant changes of mucosal thickness be-
tween treatment groups at 24 hr. At 96 hr, mucosal thickness
was significantly increased in the GLN/GH (p=0.002) and
GH (p=0.009) groups compared with the control group. The
GLN/GH group also showed a significant increase in mucos-
al thickness compared with the GLN and GH groups at 96
hr (p=0.015, p=0.009, respectively (Fig. 1B).
Gut mucosal MDA and GSH levels
While the mucosal MDA level at 24 hr was significantly
decreased in the GLN/GH compared with the control group
(p=0.002), it was significantly decreased in the GLN (p=0.015)
and GH (p=0.002) groups as well as in the GLN/GH (p=0.002)
group compared with the control group at 96 hr. The GLN/
GH group also showed lower levels of mucosal MDA than the
GLN (p=0.009) and GH (p=0.041) groups (Fig. 2A).
There was a significant increase in the mucosal GSH level in
the GLN/GH and GH groups at 24 compared with the control
(p=0.002, p=0.002, respectively) and GLN groups (p=0.004,
p=0.002, respectively). While the GH group showed a signifi-
cant increase in the mucosal GSH level at 96 hr compared the
control group (p=0.002), the GLN/GH group showed a sig-
nificant increase in the mucosal GSH level compared with the
control (p=0.002), GLN (p=0.041), and GH groups (p=0.041)
(Fig. 2B).
Correlation between parameters
There was a correlation between the bacterial colony count
and mucosal thickness. Significant correlations were also ob-
served between the colony count and gut mucosal GSH con-
tent, and between the mucosal thickness and the gut GSH
content at 96 hr. The gut mucosal MDA level showed correla-
tions to the colony count, mucosal thickness, and gut GSH
content (Table 1).
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Fig. 2. Gut MDA levels (A) and gut GSH levels (B). GLN: glutamine treatment group; GH: growth hormone treatment group; GLN/GH:
both glutamine and growth hormone treatment group. *A significant difference compared with the control group (p<0.05); #A significant
difference compared with the GLN group (p<0.05); 
� A significant difference compared with the GH group (p<0.05).
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Fig. 1. Bacterial colony counts obtained from the mesenteric lymph node culture (A). Mucosal thickness of the ileum (B). GLN: glutamine
treatment group; GH: growth hormone treatment group; GLN/GH: both glutamine and growth hormone treatment group.
*A significant difference compared with the control group (p<0.05); #A significant difference compared with the GLN group (p<0.05); 
� A
significant difference compared with the GH group (p<0.05).
*
*
* * *#�
A
GLN GH GLN/GH
M
u
c
o
s
a
l
 
T
h
i
c
k
n
e
s
s
 
(
m
) 600
500
400
300
200
100
0
24 hr 96 hr
Control
*
*#�
B
GLN GH GLN/GH20 S.-E. Jung, Y.-K. Youn, Y.-S. Lim, et al. 
DISCUSSION
Glutamine (GLN), either in enteral or parenteral form, in-
creases the intestinal villous height, maintains the mucosal in-
tegrity, and reduces BT (4). Animal studies have shown that
GLN-enriched diets shows a decreased BT and an improve-
ment in the ability to kill translocated E. coli and survival in
rats with gut-origin sepsis (6, 8). In this study, however, GLN
only treatment was not as effective as the combined treatment
of GLN and GH or GH only treatment for the prevention of
BT in septic rat. The decreased effect of GLN seems to be
caused by gut GLN depletion resulting from the impaired
intestinal GLN uptake induced by sepsis. Previous studies
have shown that sodium-dependent GLN transport by ente-
rocyte decreased in sepsis (20, 21). This decrease can be caused
by reduced availability of circulating substrate for synthesis
of carrier proteins by enterocyte, because sepsis causes a decrease
in mesenteric blood flow in the small intestine. In contrast,
GH appears to increase the intestinal GLN uptake and to
induce hepatic release of GLN in short bowel syndrome or
sepsis (22-24). It has been shown that GH increases intesti-
nal GLN uptake induced by system B amino acid transport,
and this upregulation is due, in part, to an increase in GLN
carrier capacity (25).
In previous studies, the combined treatment of GLN and
GH has been reported to initially improve the absorption of
protein, increase body weight and lean body mass, decrease
body fat, and decrease stool output in patients with short bowel
syndrome (16). In contrast, other studies showed that the com-
bination of GLN and GH did not enhance mucosal mass, mu-
cosal protein, or mucosal DNA level in rats receiving massive
small bowel resection (26), nor improved intestinal absorp-
tion, mucosal morphology, or stool losses in patients with
short bowel syndrome (27, 28). However, we showed that the
combined treatment of GLN and GH was the most effective
on BT. The synergistic effect of the combination of GLN and
GH shown in this study may result from the similar mech-
anism as noted above. Despite septic condition, gut GLN up-
take would increase markedly if GH was given simultaneous-
ly with the administration of GLN. The mechanism by which
the combination of GLN and GH exerts the synergistic effect
on BT appears to result from increased gut GLN uptake by
GH. Unneberg et al. reported a similar result in an animal
trauma model (17).
MDA, a byproduct of lipid peroxidation, is considered to be
an indicator of tissue lipid peroxidation by oxygen free radi-
cals. Lipid peroxidation of gut mucosa can result in the dis-
ruption of the mucosal barrier function followed by endotox-
emia and BT (29), and that there might be an association be-
tween BT and intestinal mucosal lipid peroxidation (30). In
our study, the gut MDA level showed positive correlation to
the bacterial colony count and negative correlation to the gut
mucosal thickness. This result suggests that there is an asso-
ciation between the gut MDA level and BT, and that the gut
MDA level may reflect the disruption of gut mucosal integri-
ty indirectly. Therefore, the reduced gut MDA level in GLN,
GH, or the combination of GLN and GH treatment in our
study indicates that these treatments decrease gut lipid per-
oxidation, maintain gut mucosal integrity, and reduce BT.
GSH, a scavenger of reactive oxygen free radicals, protects
tissues from reactive oxygen free radicals-mediated cell injury
(31). We found that GH only or the combination treatment
of GLN and GH significantly increased gut GSH contents,
but GLN only treatment did not show an increase in the gut
GSH content. These two treatment groups also showed higher
gut GSH contents than the GLN treatment group. These re-
sults suggest that GH may be more effective for the increase of
gut GSH than GLN. GH has been reported to increase plas-
ma GSH in multiple trauma patients (32), and to increase lung
and liver GSH in burned rats (33). GLN, a component of GSH,
enhances gut GSH production (34) and maintains gut GSH
levels during bowel ischemia/reperfusion (31). As noted ear-
lier, gut GLN uptake decreases in sepsis, while GH increases
gut GLN uptake. Therefore, GH appears to increase gut GSH
levels by increasing gut GLN uptake.
In this study, we measured mucosal thickness instead of mu-
cosal integrity to determine BT. Although there is some asso-
ciation between mucosal integrity and mucosal thickness, mu-
cosal integrity is different from mucosal thickness. Several stud-
ies showed that increased mucosal mass (thickness) did not
reduce BT (9, 10). Loss of mucosal integrity has been pro-
posed as promoting bacterial translocation, following adminis-
tration of endotoxin (35). Although we measured the gut
MDA level to assess the extent of the mucosal disruption
indirectly, we do not think that the gut MDA level reflect-
ed the extent of mucosal integrity accurately. For assessment of
Parameters r (24 hr) p value r (96 hr) p value
Colony counts-Mucosal thickness r=-0.556 p=0.005 r=-0.803 p<0.001
Colony counts-Gut MDA r=0.774 p<0.001 r=0.472 p=0.02
Colony counts-Gut GSH r=-0.527 p=0.008 r=-0.588 p=0.002
Mucosal thickness-Gut MDA r=-0.492 p=0.015 r=-0.674 p<0.001
Mucosal thickness-Gut GSH -- r=0.752 p<0.001
Gut MDA-Gut GSH r=-0.436 p=0.033 r=-0.719 p<0.001
Table 1. Correlation between parameters
r: correlation coefficient.mucosal integrity, further measurements including intestinal
cellular proliferation or intestinal permeability test (transmu-
cosal resistance, mannitol, lactulose, polyethylene glycol flux,
and so on) seem to be needed.
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